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MAATTERS
ARISING
Severe, disseminated, life
threatening herpes zoster
infection in a patient with
rheumatoid arthritis
treated with methotrexate
It was interesting to read the paper by van der
Veen and colleagues on the frequency and
type of infections in patients with rheumatoid
arthritis (RA) treated with methotrexate.'
Their experience concurs with that of
Antonelli et al2 who concluded that herpes
varicella zoster infection in patients with RA
receiving methotrexate therapy appears to be
self limiting and benign. I wish to report a
case of severe and systemic herpes zoster
infection in a patient with RA receiving
methotrexate.
In April 1994, a 26 year old white woman
presented to her general practitioner with a
characteristic (but non-pruritic) chicken pox
rash. She was receiving methotrexate 20 mg
weekly (Fridays), folic acid 20 mg weekly
(Tuesdays) and hydroxychloroquine 200 mg
daily for RA. Her RA had started when she
was aged 16, and it had either temporarily or
partially responded to ketoprofen, myocrisin
injections and sulphasalazine in the past.
Methotrexate was commenced at 7-5 mg
weekly in February 1993. This was effective
in suppressing her RA until August 1993
when she experienced a flare up; this was
treated with an intramuscular dose of
triamcinolone acetonide 80 mg, steroid
injections to her elbows, and an increased
dose of methotrexate (15 mg weekly). In
September 1993, her RA was still trouble-
some and her methotrexate dosage was
increased further to 20 mg weekly. When she
was still no better in November 1993,
hydroxychloroquine was added to the
regimen at 400 mg daily in the first month,
followed by a maintenance dose of 200 mg
daily. Approximately six weeks later, her
arthritis went into remission.
One week after she consulted her doctor,
the patient's rash had become so generalised
and severe that she was admitted to Timaru
Hospital. Her mucous membranes (eyes,
mouth, and vagina) were also ulcerated
(figure). She also had systemic features:
general malaise, pyrexia, tachycardia; her
blood pressure was always normal. Her full
blood count (including a white cell count
of 7-9 x 109/1 and differential count) and liver
function tests were normal a week before she
developed herpes varicella zoster infection.
Three days after admission, her white cell
count was 23-6 X 109/1 with atypical lympho-
cytes, characteristic of a viral illness. Her liver
function tests were also mildly deranged in a
hepatitic pattem and her albumin decreased
to 26 mg/l. Five days after admission, she was
mildly dyspnoeic and her chest radiographs,
which were normal on admission, had
developed features consistent with pulmonary
alveolitis. Her alveolitis was probably
secondary to disseminated varicella infection,
although we were mindful of methotrexate
induced pneumonitis.
The tongue with candida infection (obscuring the ulcers) and crops ofvaricella vesicles in
different stages.
Regular medication with Maxitrol eye
drops was started by an ophthalmologist two
days before her admission to hospital: all her
antirheumatic medications were stopped on
admission. She began receiving intravenous
hydrocortisone and broadspectrum anti-
biotics on day 3 of her inpatient treatment.
She was also given a course of oral acyclovir
although it was later in the course of her
infection than was ideal. Supportive therapy
including oxygen, analgesia, chlorhexidine
and difflam mouth washes, nystatin pastilles,
and hypnotics were also given.
Stevens-Johnson Syndrome was considered
as a differential diagnosis and attempts were
made to confirm the diagnosis of dis-
seminated varicella acutely by electron
microscopy of the vesicle fluid and skin
scrapings, but it was not possible to identify
any varicella virus. Fortunately, the patient's
condition gradually improved from day 7 of
her admission, and she was able to go home
on day 16. At the time of her discharge, the
diagnosis of disseminated varicella was
confirmed by isolation of the virus on culture
of the vesicle fluid and by demonstration of
an increase in her varicella serology from a
titre of 1/8 to 1/256. Her white cell count,
liver function tests and chest radiographs
were all normal two weeks after her
discharge. When reviewed in the clinic five
months later, she was left with some scarring
of her skin and ketoprofen alone was
sufficient to control her RA symptoms.
Although the patient has made a good
recovery, her episode of herpes varicella
zoster infection was not benign but life-
threatening. There are two reports3'4 of dis-
seminated zoster in patients with RA
receiving methotrexate, but neither indicates
any systemic or other organ involvement
beyond the skin. Both reports suggest the
acute illnesses in these patients were brief.
One ofthese patients developed disseminated
herpes varicella zoster after beginning steroids
while receiving chronic low dose metho-
trexate.4 The patient reported now was also
taking another immunomodulating drug,
hydroxychloroquine.
Review of the management of this patient
suggests zoster specific immune globulin
could have been used had she presented
within 96 hours of her contact with a relative
who had chicken pox, to reduce the severity
of her varicella infection. Had there been
a more confident diagnosis of varicella
pneumonitis, intravenous rather than oral
acyclovir should have been used.
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LETTER TO
THE EDITOR
Secondary acute myeloid
leukaemia with 7q-
complicating azathioprine
treatment for rheumatoid
arthritis
Cytotoxic agents are used increasingly in auto-
immune disorders, with resulting improve-
ment in the control and long term prognosis
of these diseases. However, there is evidence
that their prolonged use may be associated
with increased risks of solid tumours, lympho-
proliferative disorders and leukaemia.' 2 Use
of alkylating agents, advanced age, long
duration of therapy and high cumulative
doses are associated risk factors.2"
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malignant conditions is admittedly low. As it
&& r , occurs after prolonged administration of theAW 21 i drugs, physicians should be aware of this
lz ~complication. Careful clinical monitoring isimportant and use of these agents should be
minimised once the disease is under control.
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Complete karyotype showing 46, XX, del (7) (q22q35). Arrows indicate the deleted segment.
A 72 year old Chinese woman was diag-
nosed to have rheumatoid arthritis in 1979.
She was initially treated with non-steroidal
anti-inflammatory agents (diclofenac 25 mg
three times a day and naproxen 750 mg/day).
Because of disease progression, she was
given intramuscular myocrisin (aurothiomalate
sodium) from November 1979 to May 1981
(approximate cumulative dose 2400 mg).
The response was unsatisfactory. Penicillamine
750 mg/day was given from July 1981 until
May 1983, when proteinuria prevented its
further use. Levamisole 300 mg/week was
started in July 1983.
Despite this, the condition of the patient's
joints worsened and she underwent bilateral
knee replacement in 1985. Levamisole was
stopped and azathioprine 100 mg/day was
started in January 1986. She continued to
improve but developed anaemia (8-8 g/dl)
and leucopenia (2-5 X 109/1) in March
1993, necessitating reduction of azathioprine
to 50 mg/day. Further tests showed iron
deficiency, but the patient refused endo-
scopic examinations. She began taking iron
supplements; however, because of persistent
anaemia, azathioprine was substituted by
sulphasalazine 1-5 g/day in May 1993. The
total dose of azathioprine was estimated to be
260 g.
Despite transient improvement in anaemia,
her haemoglobin concentration decreased
again to 7 g/dl in June 1994. Her white cell
count was 1-5 X 109/dl (80% blasts) and
platelet count was 251 x 109/1. Bone marrow
examination showed 85% blasts. Occasional
residual erythroid precursors showed bi-
nucleation. The morphological diagnosis was
acute myeloid leukaemia (AML), M2
according to the French-American-British
Classification system for AML.5 Cytogenic
analysis was performed on marrow cells after
short term culture, metaphase chromosomes
banded by trypsin/Giemsa and karyotyped
according to the International System for
Human Cytogenetic Nomenclature 1991
Guidelines.6 This showed 46,XX,del(7)
(q22q35) (figure) in addition to a normal
clone of 46,XX. Detailed enquiry about life-
time work history and hobbies7 failed to
disclose relevant noxious agents.
Although the literature contains a few
reports relating long term use of cytotoxics or
disease modifying agents in autoimmune
disorders with the occurrence of malig-
nancies,8 9 it is difficult to determine if these
observations represent a causal relationship
or chance occurrence. However, in the
present case, several features support
the diagnosis of secondary leukaemia. The
presence of myelodysplastic features, albeit
subtle, in residual haematopoietic elements,
together with the one year history of anaemia
preceding the leukaemia, suggest a pre-
leukaemic phase before the onset of frank
leukaemia. The strongest supporting evidence
was the chromosomal abnormality. Karyo-
typic aberrations involving chromosome
7-either deletion of the long arm (7q-) or
monosomy (-7) are common chromosomal
aberrations in AML and myelodysplasia,'°
and are significantly related to leukaemias
secondary to toxic exposures including
environmental and occupational toxins,1' 12
and previous chemotherapy.'3 Thus, 7q-/-7
can be considered a characteristic finding in
secondary leukaemia.'3 14
A detailed examination of the drug history
of this patient revealed three candidate
causative drugs: myocrisin, penicillamine
and azathioprine. Although myocrisin and
penicillamine cause myelosuppression and
aplastic anaemia, no case of secondary
leukaemia or malignancies has been
attributed to their use. However, acute
leukaemia had been reported in a patient with
systemic lupus erythematosus/rheumatoid
arthritis overlap syndrome treated with a total
cumulative dose of 52 g of azathioprine.'"
The authors of that report suggested that,
because of the small cumulative dose, further
studies were required. With the much greater
cumulative dose in our patient (260 g) and
the characteristic chromosomal aberration,
we conclude that azathioprine was the most
likely leukaemogenic drug in our patient.
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